NMC Royal Khalifa City: A lifeline for women facing Placenta Accreta Spectrum Disorder
In June 2023, NMC Royal Hospital, Khalifa City, proudly launched its Placenta Accreta Spectrum Disorder (PASD) Program, a groundbreaking initiative offering world-class care for expectant mothers diagnosed with this high-risk condition. Over the past year, 10 women have successfully undergone treatment through this program with each receiving expert, multidisciplinary care tailored to their unique medical needs.
For women diagnosed with PASD, the journey can be overwhelming due to the potential complications involved. The condition, where the placenta embeds too deeply into the uterine wall, poses serious risks during childbirth, often leading to severe bleeding and in many cases, the need for a hysterectomy. This is where the highly specialized PASD team at NMC Royal Hospital, Khalifa City is transforming the standard approach by providing innovative, patient-centred solutions that prioritize both safety and fertility preservation.
What sets our PASD program apart is our personalized and highly coordinated treatment protocol. Each patient undergoes thorough evaluation, including an MRI confirmation, enabling detailed pre-operative planning and ensuring every expecting mother receives an individualized care plan tailored to her specific condition. Our multidisciplinary team, which collaborates on every PASD case, includes obstetricians, maternal-fetal medicine specialist, interventional radiologists, urologists, anesthesiologists, intensive care specialists and a highly skilled surgical team.
In many hospitals, a hysterectomy – the surgical removal of the uterus - is often the standard course of action for managing PASD to prevent life-threatening complications. Through our advanced PASD protocols, state-of-the-art facilities and the expertise of our multidisciplinary team, none of the women treated in our PASD program have required a hysterectomy. Furthermore, blood loss was minimal across all cases, resulting in significantly faster recovery and improved long-term maternal health outcomes. This represents a major advancement in PASD treatment, offering women not only hope but also the opportunity to preserve fertility while ensuring the safest possible delivery.
Placenta Accreta Spectrum Disorder (PASD) is one of the most complex pregnancy-related conditions and its management requires expertise, experience and a well-integrated team approach that adapts to each individual case. Early diagnosis and meticulous planning can make all the difference in ensuring safer deliveries and better maternal health outcomes.
At NMC Royal Hospital, Khalifa City, we are committed to leading the way in PASD care, constantly driving innovation to set new benchmarks in women's health. Our unwavering commitment ensures that every woman facing this condition receives not only the highest level of medical treatment but also the compassion, reassurance and support she deserves.
Our dedication to continuous innovation and excellence in maternal-fetal care ensures that every expecting mother who walks through our doors receives the safest and most effective treatment available today.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Etihad
02-06-2025
- Al Etihad
Pulse and hopes high when healthcare and Al hold hands
3 June 2025 01:00 EISSA ALI ALMANNEI *Technological progress sometimes affects human lives slightly and sometimes in profound ways. But when it empowers vital sectors like healthcare, the hopes pinned on this technological revolution increase. This is exactly the case with harnessing artificial intelligence in the healthcare industry and the adoption of AI tools by healthcare institutions to assist at every stage of the care language models, chatbots, and voice assistants are now integrated into AI-powered workflows across clinics and hospitals, helping in internal processes and medical records. AI can improve operations, from human resources to insurance claims, facilitating data management and applying AI tools to generate automated reports and resource utilisation metrics in real saves a lot of time on administrative tasks and interactions while reducing costs. AI is not limited to administrative and financial operations. In fact, it can give anonymous patient data, such as MRI scans, CT images, lab results, and clinical notes, to feed AI diagnostic radiology, AI helps doctors transcend the limitations of the human eye, as it trains algorithms to reconstruct blurry images and highlight areas of concern, such as tumors or fractures. With big data and patient record analysis, healthcare professionals can detect patterns and risk factors that might be missed in traditional diagnostic of the fundamental advantages of AI in healthcare is its ability to improve diagnostic accuracy and treatment plans, which enables faster decision-making by providing physicians with precise, real-time information. In emergencies, where time is critical to saving lives, AI-assisted robotics can improve surgical outcomes, aid surgeons in enhancing precision, reduce complications, and improve patient the pharmaceutical sector, companies rely on AI to analyse chemical composition databases, protein interactions, and side effects. This not only accelerates drug development but also increases the success rate of new medications while improving safety and reducing the risk of adverse reactions. AI can even predict individual responses to treatments by analysing genetic profiles and medical histories and discovering how a specific gene variant affects drug addition, AI can simulate patients in clinical training, allowing students to adapt to various cases. Virtual patients respond in real time to what the student says or does, creating a more realistic experience. AI is also being used in mental health, guiding cancer survivors through post-treatment care, and assisting in the early detection of diseases, including certain types of AI is still relatively new in healthcare, there is now a smart hospital in China operated by fourteen AI-powered virtual doctors who diagnose and treat patients without any human staff. This virtual team is capable of treating over 3,000 patients daily. This implies that AI's ability to match, or even exceed, human diagnostic capabilities in terms of accuracy and speed is within there are challenges related to the ambiguity of AI models to physicians, making it difficult to understand how they arrive at conclusions. This lack of clarity can confuse doctors when they cannot grasp the reasons behind an algorithm's there are concerns about protecting patients' medical privacy, as AI relies on massive datasets that frequently contain sensitive health information. AI outcomes can also be biased due to disparities or differences in training data, leading to distorted results. Therefore, the quality and balance of the data used to train these models are critical to ensuring accurate and reliable hopes for AI in healthcare are undeniable. Medical AI systems can process information faster than any human doctor, but caution is needed to address challenges, use data analysis and advanced analytics, and continue developing technologies that aid in disease diagnosis, prevention, personalised treatment, and drug development to improve the quality of human life. * The writer is a researcher at TRENDS Research & Advisory
Al Etihad
14-05-2025
- Al Etihad
New Thalassemia and Sickle Cell Centre opened at Burjeel Medical City in Abu Dhabi
14 May 2025 22:26 ABU DHABI (ALETIHAD)Burjeel Holdings has launched a Thalassemia and Sickle Cell Centre at Burjeel Medical City (BMC) in Abu Dhabi, marking a significant step towards redefining the standard of care for individuals with inherited blood launch took place under the patronage and in the presence of Sheikha Shaikha bint Saif bin Mohamed Al Nahyan, wife of Sheikh Dr. Sultan bin Khalifa Al Nahyan, Advisor to His Highness the President and Chairperson of the Emirates Thalassemia her opening speech on the occasion, Sheikha Shamma said, "In my mother's unwavering commitment to thalassemia patients, I have witnessed how compassion, when paired with vision and persistence, can transform countless lives across generations and beyond borders."The newly inaugurated Thalassemia and Sickle Cell Centre by Burjeel Holdings' state-of-the-art facility will provide compassionate and comprehensive care to patients and their families," she centre was inaugurated in a grand ceremony also attended by Sheikh Khalifa bin Sultan bin Khalifa Al Nahyan, Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings, Omran Al Khoori, Board Member, and a number of Burjeel opening was also attended by members of the Board of Directors of the Emirates Thalassemia Society, and a number of leaders from the Department of Health in Abu centre supports individuals living with thalassemia and sickle cell disease by delivering a holistic, patient-centric, and evidence-based model of care, supported by a multidisciplinary team of world-renowned experts. The centre offers fully integrated outpatient services and a dedicated transfusion unit operating seven days a week. The centre is distinguished by several key differentiators, including extended transfusion services across the UAE via Burjeel's hospital network, internationally validated MRI quantification of iron overload in the heart and liver, and in-house molecular genotyping capabilities. Prof. Khaled Musallam, Group Chief Research Officer of Burjeel Holdings and Director of the Thalassemia and Sickle Cell Centre, said, "What makes this centre unique is the combination of global clinical expertise, access to the latest therapies, and the ability to deliver care in line with international guidelines authored by the very people leading the services here."With an international advisory board of global key opinion leaders, the centre adheres to leading global standards, including those of the Thalassaemia International Federation, with necessary local adaptations to meet patients' centre will also work closely with the Centre for Research on Rare Blood Disorders (CR-RBD) at BMC, also headed by Prof. Khaled Musallam, to identify and enroll eligible patients in global clinical trials, ensuring access to the latest innovations in treatment, including disease-modifying and curative has swiftly become recognised as one of the most active hubs for research on haheemoglobin disorders globally. Source: Aletihad - Abu Dhabi
Al Etihad
14-05-2025
- Al Etihad
Under the patronage of Sheikha bint Saif, Burjeel Holdings launches Thalassemia and Sickle Cell Centre
14 May 2025 10:11 ABU DHABI (ALETIHAD)Under the patronage of Sheikha Shaikha bint Saif bin Mohamed Al Nahyan, wife of His Highness Sheikh Sultan bin Khalifa Al Nahyan, Advisor to His Highness the President, and Chairperson of the Emirates Thalassemia Society, Burjeel Holdings has launched a Thalassemia and Sickle Cell Centre at its flagship quaternary care hospital, Burjeel Medical City (BMC) in Abu Dhabi, in a step towards redefining the standard of care for individuals with inherited blood centre was inaugurated in a grand ceremony also attended by Sheikh Khalifa bin Sultan bin Khalifa Al Nahyan, Dr Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings, Omran Al Khoori, Board Member, and a number of Burjeel leaders. The opening was also attended by members of the Board of Directors of the Emirates Thalassemia Society and a number of leaders from the Department of Health, Abu Shamma bint Sultan bin Khalifa Al Nahyan said in the opening speech she delivered on this occasion: "In my mother's unwavering commitment to thalassemia patients, I have witnessed how compassion, when paired with vision and persistence, can transform countless lives across generations and beyond borders. The newly inaugurated Thalassemia and Sickle Cell Centre by Burjeel Holdings' state-of-the-art facility will provide compassionate and comprehensive care to patients and their families."The centre supports individuals living with thalassemia and sickle cell disease by delivering a holistic, patient-centric, and evidence-based model of care, supported by a multidisciplinary team of world-renowned centre offers fully integrated outpatient services and a dedicated transfusion unit operating seven days a week. The centre is distinguished by several key differentiators, including extended transfusion services across the UAE via Burjeel's hospital network, internationally validated MRI quantification of iron overload in the heart and liver, and in-house molecular genotyping capabilities. Patients are cared for by experts with decades of experience in managing both pediatric and adult cases of thalassemia and sickle cell disease. With the MENA region reporting considerably high prevalence rates of thalassemia and sickle cell disease, the centre aims to bridge critical gaps in long-term care. The centre's strategic location within a quaternary care facility ensures direct access to advanced medical and surgical subspecialties, enabling seamless referrals and comprehensive management of Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, and Director of the Thalassemia & Sickle Cell Centre, said: 'Our goal is to establish the Thalassemia and Sickle Cell Centre as a regional hub for cutting-edge care and research in rare blood disorders. What makes this centre unique is the combination of global clinical expertise, access to the latest therapies, and the ability to deliver care in line with international guidelines authored by the very people leading the services here. We are not only focused on treatment, but also on improving patients' quality of life and future outcomes through holistic, personalised care.'With an international advisory board of global key opinion leaders, the centre adheres to leading global standards, including those of the Thalassaemia International Federation, with necessary local adaptations to meet the specific needs of patients in the UAE and MENA region. Its continuum of care begins at diagnosis and spans childhood to adulthood, with tailored transition programmes and advanced treatments for conditions including transfusion-dependent β-thalassemia (TDT), non-transfusion-dependent β-thalassemia (NTDT), and sickle cell disease. The centre will also work closely with the Centre for Research on Rare Blood Disorders (CR-RBD) at BMC, also headed by Prof Khaled Musallam, to identify and enrol eligible patients in global clinical trials, ensuring access to the latest innovations in treatment, including disease-modifying and curative therapies. Source: Aletihad - Abu Dhabi
